Axsome Therapeutics (MEX:AZSM) Cyclically Adjusted Book per Share: MXN20.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZSM Axsome Therapeutics Inc MEX:AZSM
52 GF Score
Price MXN1,519.00
GF Value MXN1,494.25
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics Cyclically Adjusted Book per Share?

Axsome Therapeutics MEX:AZSM 52 Cyclically Adjusted Book per Share is MXN20.13 as of Mar. 2026. GuruFocus rates MEX:AZSM with a GF Score™ of 52/100 and a GF Value™ of MXN1,494.25. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Axsome Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was MXN19.143. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN20.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Axsome Therapeutics's average Cyclically Adjusted Book Growth Rate was 2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-14), Axsome Therapeutics's current stock price is MXN1519.00. Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN20.13. Axsome Therapeutics's Cyclically Adjusted PB Ratio of today is 75.46.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Axsome Therapeutics was 113.92. The lowest was 32.96. And the median was 49.08.


Axsome Therapeutics  (MEX:AZSM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Axsome Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1519.00/20.13
=75.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Axsome Therapeutics was 113.92. The lowest was 32.96. And the median was 49.08.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Axsome Therapeutics Cyclically Adjusted Book per Share Related Terms


Axsome Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Cyclically Adjusted Book per Share Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 39.14 18.71

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.39 32.74 28.64 18.71 20.13

MEX:AZSM vs MDGL, IONS, BMRN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Cyclically Adjusted PB Ratio falls into.


MEX:AZSM
52GF Score
Axsome Therapeutics Inc MEX:AZSM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Axsome Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.143/330.2130*330.2130
=19.143

Current CPI (Mar. 2026) = 330.2130.

Axsome Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 33.709 241.018 46.184
201609 28.452 241.428 38.915
201612 23.214 241.432 31.750
201703 23.416 243.801 31.715
201706 17.423 244.955 23.487
201709 12.913 246.819 17.276
201712 12.879 246.524 17.251
201803 8.949 249.554 11.841
201806 5.246 251.989 6.874
201809 0.525 252.439 0.687
201812 0.612 251.233 0.804
201903 10.120 254.202 13.146
201906 13.587 256.143 17.516
201909 3.905 256.759 5.022
201912 91.265 256.974 117.276
202003 98.761 258.115 126.347
202006 95.531 257.797 122.366
202009 80.015 260.280 101.514
202012 60.565 260.474 76.781
202103 52.399 264.877 65.324
202106 37.771 271.696 45.906
202109 23.306 274.310 28.056
202112 8.479 278.802 10.043
202203 7.526 287.504 8.644
202206 7.661 296.311 8.538
202209 72.890 296.808 81.094
202212 49.102 296.797 54.630
202303 46.280 301.836 50.631
202306 102.630 305.109 111.074
202309 99.214 307.789 106.442
202312 68.461 306.746 73.698
202403 50.363 312.332 53.246
202406 39.418 314.175 41.430
202409 37.765 315.301 39.551
202412 24.433 315.605 25.564
202503 22.116 319.799 22.836
202506 27.621 322.561 28.276
202509 26.884 324.800 27.332
202512 31.244 324.054 31.838
202603 19.143 330.213 19.143

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN20.13 mean?
Axsome Therapeutics (MEX:AZSM) has a Cyclically Adjusted Book per Share of MXN20.13 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Cyclically Adjusted Book per Share too high?
Axsome Therapeutics' current Cyclically Adjusted Book per Share is MXN20.13. Overall, Axsome Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Cyclically Adjusted Book per Share compare to MDGL and IONS?
Axsome Therapeutics' Cyclically Adjusted Book per Share of MXN20.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Cyclically Adjusted Book per Share is MXN20.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Axsome Therapeutics (MEX:AZSM) has a current Cyclically Adjusted Book per Share of MXN20.13. The stock's GF Value™ is MXN1,494.25, compared to a current price of MXN1,519.00 — trading 1.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN20.13. Axsome Therapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Axsome Therapeutics (MEX:AZSM), the current Cyclically Adjusted Book per Share is MXN20.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (MEX:AZSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of MXN1,519.00 is trading 1.7% above its estimated GF Value™ of MXN1,494.25.

Key valuation signals for MEX:AZSM:

  • Cyclically Adjusted Book per Share: MXN20.13
  • GF Value™: MXN1,494.25 vs. price of MXN1,519.00 (1.7% above fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for MEX:AZSM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,519.00
Price
MXN1,494.25
GF Value